Hanmi set Eppe's first four weeks at 129,800 won ahead of a late-month launch, while Novo seeks Korean insurance coverage for Wegovy in high-risk patients.
Recap by typeshit. Full story at Korea JoongAng Daily.
About half of Australia's roughly 500,000 GLP-1 users pay privately, A$200 to $700 a month, and the authors argue cost hits those with the most obesity hardest.
Ireland's drug pricing body recommended semaglutide over tirzepatide for cost reasons, and Higgins says it's the right call, with a pun he didn't get to use.
The Turkish professor claims income from weight loss shots now far exceeds total AI revenue, a comparison he makes without sourcing in the snippet.
Researchers tracked 8,914 insured patients in JAMA Health Forum. Above $75 out of pocket, nonadherence topped 80%, says author Eunhae Shin.
In rats and minipigs, doses too small to cut weight still reduced heart scarring and stiffness tied to a common heart failure type, researchers report.
2:12
A short explainer on the experimental injection people call Reta, covering why it went viral and what is known so far about its safety.
Loading…